Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 2/2015

01.06.2015 | Original Article

Molecular Characterization of β-Thalassemia in Nineveh Province Illustrates the Relative Heterogeneity of Mutation Distributions in Northern Iraq

verfasst von: Adil A. Eissa, Muna A. Kashmoola, Sulav D. Atroshi, Nasir A. S. Al-Allawi

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Beta thalassemia is an important health problem in Nineveh province, a large province in Northwestern Iraq. No previous study of significance had focused on the spectrum of β-thalassemia mutations in this part of the country. A total of 94 unrelated β-thalassemia minor subjects from the latter province were recruited. Their carrier status was confirmed by full blood count, Hb A2 and F estimation. Thereafter their DNA was subjected to multiplex polymerase chain reaction and reverse hybridization to detect 20 β-thalassemia mutations. A total of eleven different β-thalassemia mutations were documented. The most frequent mutation was IVS-I-110 (G>A) documented in 34 %, followed by IVS-I-6 (T>C) in 9.6 %, IVS-I-5(G>C) in 8.5 %, codon 39 (C>T) and codon 44 (−C) in 7.4 % each, while IVS-I-1(G>A) and IVS-II-1(G>A) were encountered in 6.4 % each. Other mutations were less frequent including codon 8 (−AA), IVS-I-130 (G>C), codon 5 (−CT) and IVS-II-745(C>G). The current study revealed notable differences in the relative frequencies of several β-thalassemia mutations in Nineveh province as compared to other parts of Northern Iraq. Such an observation may be reflective of different ethnic backgrounds and varying historical population interactions. It is believed that these findings complement those of earlier studies on β-thalassemia mutations from the country, and are quite essential in the setting of a proposed national preventive program.
Literatur
1.
Zurück zum Zitat Weatherall DJ, Clegg JB (2001) The thalassaemia syndromes, 4th edn. Blackwell, OxfordCrossRef Weatherall DJ, Clegg JB (2001) The thalassaemia syndromes, 4th edn. Blackwell, OxfordCrossRef
3.
Zurück zum Zitat Hamamy H, Al-Allawi N (2013) The epidemiology of haemoglobinopathies in Arab countries. J Commun Genet 4:147–167CrossRef Hamamy H, Al-Allawi N (2013) The epidemiology of haemoglobinopathies in Arab countries. J Commun Genet 4:147–167CrossRef
6.
Zurück zum Zitat Jalal S, Al-Allawi N, Bayat N, Imanian H, Najmabadi H, Faraj A (2010) Beta thalassemia mutations in the Kurdish population of Northeastern Iraq. Hemoglobin 34:469–476CrossRefPubMed Jalal S, Al-Allawi N, Bayat N, Imanian H, Najmabadi H, Faraj A (2010) Beta thalassemia mutations in the Kurdish population of Northeastern Iraq. Hemoglobin 34:469–476CrossRefPubMed
8.
Zurück zum Zitat Al-Allawi N, Jubrael J, Hughson M (2006) Molecular characterization of β thalassemias in Dohuk Region of Iraq. Hemoglobin 30:479–486CrossRefPubMed Al-Allawi N, Jubrael J, Hughson M (2006) Molecular characterization of β thalassemias in Dohuk Region of Iraq. Hemoglobin 30:479–486CrossRefPubMed
9.
Zurück zum Zitat Galanello R, Eleftheriou A, Traaeger-Synedions J, Petrou M, Angastiniotis M (2003) Prevention of thalassemia and othe hemoglobin disorders, vol 1. TIF Publications, Nicosia Galanello R, Eleftheriou A, Traaeger-Synedions J, Petrou M, Angastiniotis M (2003) Prevention of thalassemia and othe hemoglobin disorders, vol 1. TIF Publications, Nicosia
10.
Zurück zum Zitat Altay C (2002) The frequency and distribution pattern of β-thalassemia mutations in turkey. Turk J Hematol 19:309–315 Altay C (2002) The frequency and distribution pattern of β-thalassemia mutations in turkey. Turk J Hematol 19:309–315
11.
Zurück zum Zitat Makhoul NJ, Wells RS, Kaspar H, Shbaklo H, Taher A, Chakar N, Zalloua PA (2005) Genetic heterogeneity of beta thalassemia in Lebanon reflects historic and recent population migration. Ann Hum Genet 69:55–66CrossRefPubMed Makhoul NJ, Wells RS, Kaspar H, Shbaklo H, Taher A, Chakar N, Zalloua PA (2005) Genetic heterogeneity of beta thalassemia in Lebanon reflects historic and recent population migration. Ann Hum Genet 69:55–66CrossRefPubMed
12.
Zurück zum Zitat Kyriacou K, Al QF, Pavlou E, Christopoulos G, Ioannou P, Kleanthous M (2000) Molecular characterization of beta-thalassemia in Syria. Hemoglobin 24:1–13CrossRefPubMed Kyriacou K, Al QF, Pavlou E, Christopoulos G, Ioannou P, Kleanthous M (2000) Molecular characterization of beta-thalassemia in Syria. Hemoglobin 24:1–13CrossRefPubMed
13.
Zurück zum Zitat Najmabadi H, Karimi-Nejad R, Sahebjam S, Pourfarzad F, Teimourian S, Sahebjam F, Amirizadeh N, Karimi-Nejad MH (2001) The beta-thalassemia mutation spectrum in the Iranian population. Hemoglobin 25:285–296CrossRefPubMed Najmabadi H, Karimi-Nejad R, Sahebjam S, Pourfarzad F, Teimourian S, Sahebjam F, Amirizadeh N, Karimi-Nejad MH (2001) The beta-thalassemia mutation spectrum in the Iranian population. Hemoglobin 25:285–296CrossRefPubMed
14.
Zurück zum Zitat Jiffri EH, Bogari N, Zidan KH, Teama S, Elhawary NA (2010) Molecular updating of β-thalassemia mutations in the upper Egyptian population. Hemoglobin 34:538–547CrossRefPubMed Jiffri EH, Bogari N, Zidan KH, Teama S, Elhawary NA (2010) Molecular updating of β-thalassemia mutations in the upper Egyptian population. Hemoglobin 34:538–547CrossRefPubMed
15.
Zurück zum Zitat Sadiq MF, Eigel A, Horst J (2001) Spectrum of β-thalassemia in Jordan: identification of two novel mutations. Am J Hematol 68:16–22CrossRefPubMed Sadiq MF, Eigel A, Horst J (2001) Spectrum of β-thalassemia in Jordan: identification of two novel mutations. Am J Hematol 68:16–22CrossRefPubMed
16.
Zurück zum Zitat Tadmouri GO, Tüzmen S, Özçelik H, Özer A, Baig SM, Senga EB, Başak AN (1998) Molecular and population genetic analyses of β-thalassemias in Turkey. Am J Hematol 57:215–220CrossRefPubMed Tadmouri GO, Tüzmen S, Özçelik H, Özer A, Baig SM, Senga EB, Başak AN (1998) Molecular and population genetic analyses of β-thalassemias in Turkey. Am J Hematol 57:215–220CrossRefPubMed
17.
Zurück zum Zitat Başak AN (2007) The molecular pathology of β-thalassemia in Turkey: the Boǵaziçi university experience. Hemoglobin 31:233–241CrossRefPubMed Başak AN (2007) The molecular pathology of β-thalassemia in Turkey: the Boǵaziçi university experience. Hemoglobin 31:233–241CrossRefPubMed
18.
Zurück zum Zitat Őner R, Altay C, Gurgey A, Aksoy M, Kilinc Y, Stoming TA, Reese AL, Kutlar A, Kutlar F, Huisman THJ (1990) β-Thalassemia in Turkey. Hemoglobin 14:1–13CrossRefPubMed Őner R, Altay C, Gurgey A, Aksoy M, Kilinc Y, Stoming TA, Reese AL, Kutlar A, Kutlar F, Huisman THJ (1990) β-Thalassemia in Turkey. Hemoglobin 14:1–13CrossRefPubMed
19.
Zurück zum Zitat Tadmouri GO (1999) β-thalassemia in Turkey: distribution, diversity, evaluation and phenotype-genotype correlations. PhD thesis. Boǵaziçi University. Turkey Tadmouri GO (1999) β-thalassemia in Turkey: distribution, diversity, evaluation and phenotype-genotype correlations. PhD thesis. Boǵaziçi University. Turkey
20.
Zurück zum Zitat Al-Allawi NAS, Al-Mousawi BMS, Badi AIA, Jalal SD (2013) The spectrum of β-thalassemia mutations in Baghdad, Central Iraq. Hemoglobin 37:444–453CrossRefPubMed Al-Allawi NAS, Al-Mousawi BMS, Badi AIA, Jalal SD (2013) The spectrum of β-thalassemia mutations in Baghdad, Central Iraq. Hemoglobin 37:444–453CrossRefPubMed
21.
Zurück zum Zitat Tamagnini GP, Lopes MC, Castanheira ME, Wainscot JS, Wood WG (1983) β+Thalassaemia—Portuguese type: clinical, haematological and molecular studies of a newly defined form of β-thalassaemia. Br J Haematol 54:189–200 Tamagnini GP, Lopes MC, Castanheira ME, Wainscot JS, Wood WG (1983) β+Thalassaemia—Portuguese type: clinical, haematological and molecular studies of a newly defined form of β-thalassaemia. Br J Haematol 54:189–200
22.
Zurück zum Zitat El-Latif MA, Filon D, Rund D, Oppenheim A, Kanaan M (2002) The β+-IVS-I-6 (T→C) mutation accounts for half of the thalassemia chromosomes in the Palestinian populations of the mountain regions. Hemoglobin 26:33–40CrossRefPubMed El-Latif MA, Filon D, Rund D, Oppenheim A, Kanaan M (2002) The β+-IVS-I-6 (T→C) mutation accounts for half of the thalassemia chromosomes in the Palestinian populations of the mountain regions. Hemoglobin 26:33–40CrossRefPubMed
23.
Zurück zum Zitat Gupta A, Sarwai S, Pathak N, Agarwal S (2008) Beta-globin gene mutations in India and their linkage to β-haplotypes. Int J Hum Genet 8:237–241 Gupta A, Sarwai S, Pathak N, Agarwal S (2008) Beta-globin gene mutations in India and their linkage to β-haplotypes. Int J Hum Genet 8:237–241
24.
Zurück zum Zitat Old JM, Khan SN, Verma I, Fucharoen S, Kleanthous M, Ioannou P, Kotea N, Fisher C, Riazuddin S, Saxena R, Winichagoon P, Kyriacou K, Al-Quobaili F, Khan B (2001) A multi-center study in order to further define the molecular basis of β-thalassemia in Thailand, Pakistan, Sri Lanka, Mauritius, Syria, and India, and to develop a simple molecular diagnostic strategy by amplification refractpry mutation system—polymerase chain reaction. Hemoglobin 25:397–407CrossRefPubMed Old JM, Khan SN, Verma I, Fucharoen S, Kleanthous M, Ioannou P, Kotea N, Fisher C, Riazuddin S, Saxena R, Winichagoon P, Kyriacou K, Al-Quobaili F, Khan B (2001) A multi-center study in order to further define the molecular basis of β-thalassemia in Thailand, Pakistan, Sri Lanka, Mauritius, Syria, and India, and to develop a simple molecular diagnostic strategy by amplification refractpry mutation system—polymerase chain reaction. Hemoglobin 25:397–407CrossRefPubMed
25.
Zurück zum Zitat Patrinos GP, Giardine B, Riemer C, Miller W, Chui DKH, Anagnou NP, Wajcman H, Hardison RC (2004) Improvement in HbVar Database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res 32 (Database issue): D537–D541 (http://globin.sce.psu.edu) Patrinos GP, Giardine B, Riemer C, Miller W, Chui DKH, Anagnou NP, Wajcman H, Hardison RC (2004) Improvement in HbVar Database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res 32 (Database issue): D537–D541 (http://​globin.​sce.​psu.​edu)
26.
Zurück zum Zitat Nerweiy FF, Al-Allawi NA, Jubrael J, Dawood RS (2010) The application of the amplification refractory mutation system (ARMS) for characterization β-thalassaemia mutations in Duhok. Duhok Med J 4:8–20 Nerweiy FF, Al-Allawi NA, Jubrael J, Dawood RS (2010) The application of the amplification refractory mutation system (ARMS) for characterization β-thalassaemia mutations in Duhok. Duhok Med J 4:8–20
Metadaten
Titel
Molecular Characterization of β-Thalassemia in Nineveh Province Illustrates the Relative Heterogeneity of Mutation Distributions in Northern Iraq
verfasst von
Adil A. Eissa
Muna A. Kashmoola
Sulav D. Atroshi
Nasir A. S. Al-Allawi
Publikationsdatum
01.06.2015
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 2/2015
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-014-0369-1

Weitere Artikel der Ausgabe 2/2015

Indian Journal of Hematology and Blood Transfusion 2/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.